Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cyclerion Therapeutics, Inc.

https://www.cyclerion.com/

Latest From Cyclerion Therapeutics, Inc.

Deal Watch: AstraZeneca Out-Licenses Pneumonia Candidate, Obtains STING Inhibitors

Pharma moves Phase III-ready antibody to prevent pneumonia to Aridis, licenses preclinical STING inhibitors from F-star. Sanofi teams with SRI on AI-directed discovery, Biogen licenses BTK inhibitor from InnoCare.

Deal Watch Business Strategies

Deal Watch: AbbVie To Try Caraway’s Lysosomal Function Approach To Parkinson’s

Akebia brings in Cyclerion’s diabetes candidate praliciguat, plus deals involving Genmab/Bolt, Auris/Trasir, Zymergen/Lodo, Bavarian Nordic/Dynavax and more.

Deals Business Strategies

Ironwood Ends Phase III GERD Program, Will Cut 100 Jobs

The company has no development programs left in its R&D pipeline and will focus entirely on the commercialization of IBS drug Linzess while seeking late-stage assets from external sources.

Clinical Trials Gastrointestinal

Cyclerion Looking To Partner Praliciguat Despite Phase II Fail In Diabetic Nephropathy

The Ironwood spinout thinks its sGC stimulator demonstrated benefit in reducing urine albumin levels in DN patients; notes data improve markedly if one outlier trial site is excluded.

Clinical Trials Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
UsernamePublicRestriction

Register